Chimeric zinc finger recombinases optimized for catalysis by directed evolution
The present invention is directed to chimeric recombinases comprising a serine recombinase operatively linked to a zinc finger nucleotide binding domain such that the chimeric recombinase protein catalyzes site-specific recombination at a DNA site specifically bound by the zinc finger nucleotide binding domain. The serine recombinase can be one of several naturally occurring serine recombinases. The invention also includes nucleic acids encoding the chimeric recombinases, vectors including the nucleic acids, host cells transformed or transfected with the vectors, methods of using the chimeric recombinases to carry out recombination, methods of using substrate-linked protein evolution to generate additional chimeric recombinases, methods of using the chimeric recombinases for gene therapy, and pharmaceutical compositions.
1. A chimeric recombinase protein comprising a serine recombinase operatively linked to a zinc finger nucleotide binding domain such that the chimeric recombinase protein catalyzes site-specific recombination at a DNA site specifically bound by the zinc finger nucleotide binding domain and,
wherein the serine recombinase is a Gin mutein having the following mutation M70V with reference to a wild-type Gin serine recombinase comprising the amino acid sequence as set forth in SEQ ID NO: 707, and one or more of the following mutations: D12G, N14S, N20D, K50E, I94V and M114V with reference to the wild-type Gin serine recombinase, and
wherein the zinc finger nucleotide binding domain is selected from the group consisting of a bidactyl zinc finger binding domain that binds a hexanucleotide, a tridactyl zinc finger nucleotide binding domain that binds 9 base pairs, a 4-finger zinc finger nucleotide binding domain that binds 12 base pairs, a 5-finger zinc finger nucleotide binding domain that binds 15 base pairs, and a 6-finger zinc finger nucleotide binding domain that binds 18 base pairs.
2. The chimeric recombinase protein of claim 1 , wherein the serine recombinase is a Gin mutein having the following mutations with reference to the wild-type Gin serine recombinase: D12G, N14S, N20D, K50E, M70V, I94V and M 114V.
3. The chimeric recombinase protein of claim 2 , wherein the zinc finger nucleotide binding domain binds the 9-bp sequence GGAGGCGTG (SEQ ID NO: 634).
4. The chimeric recombinase protein of claim 1 , wherein the zinc finger nucleotide binding domain comprises at least one oligopeptide linker located between triplet binding domains.
5. The chimeric recombinase protein of claim 1 , wherein the oligopeptide linker is TGEKP (SEQ ID NO: 624).
6. A chimeric recombinase protein obtained from the chimeric recombinase protein of claim 1 by one to five conservative amino acid substitutions, wherein the conservative amino acid substitutions are each selected from the following substitutions: Ala/Gly or Ser; Arg/Lys; Asn/Gln or His; Asp/Glu; Cys/Ser; Gln/Asn; Gly/Asp; Gly/Ala or Pro; His/Asn or Gln; Ile/Leu or Val; Leu/Ile or Val; Lys/Arg or Gln or Glu; Met/Leu or Tyr or Ile; Phe/Met or Leu or Tyr; Ser/Thr; Thr/Ser; Trp/Tyr; Tyr/Trp or Phe; Val/Ile or Leu, and wherein the chimeric recombinase protein obtained by the conservative amino acid substitutions has the same DNA sequence specificity for recombination as the unmutated chimeric recombinase, has a binding affinity for the substrate of no less than about 80% of the binding affinity for the substrate of the unmutated chimeric recombinase, and has a Vmax of no less than about 80% of the Vmax of the unmutated chimeric recombinase.
7. The chimeric recombinase protein of claim 1 , wherein the chimeric recombinase protein further includes at least one additional domain.
8. The chimeric recombinase protein of claim 7 , wherein the additional domain is selected from the group consisting of a purification tag, an enzyme domain, a ligand binding domain, a cell penetrating domain, and an enzyme domain that catalyzes the detectable production of light via fluorescence or bioluminescence.
9. A composition comprising:
(a) the chimeric recombinase protein of claim 1 ; and
(b) a pharmaceutically acceptable carrier.